A Novel Orally Bioavailable Inhibitor of Kinase Insert Domain-Containing Receptor Induces Antiangiogenic Effects and Prevents Tumor Growth <b> <i>in Vivo</i> </b>
Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Kenneth A. Thomas(United States Military Academy), Xianzhi Mao(United States Military Academy), David Heimbrook(United States Military Academy), Susan L. Hill(United States Military Academy), Elaine Rands, Jennifer M. Shipman(Johns Hopkins University), Nancy E. Kohl(United States Military Academy), George D. Hartman(Joint BioEnergy Institute), Keith Rickert(United States Military Academy), Kathleen Coll(United States Military Academy), W. Wayt Gibbs(United States Military Academy), Joanne Antanavage(Institute of Cancer Research), Brett Connolly(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephen C. Beck(United States Military Academy), William F. Hoffman(United States Military Academy), Mark E. Fraley(United States Military Academy), Lenora J. Davis(Institute of Cancer Research), Patrice A. Ciecko(United States Military Academy)
Cited by 26
Related Papers
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Total Synthesis of Spirotryprostatin A, Leading to the Discovery of Some Biologically Promising Analogues
|Journal of the American Chemical Society|1999|463
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
|Cancer Immunology Research|2015|440
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
|Proceedings of the National Academy of Sciences|1996|409